Fraction of Nursing Home Admissions Attributable to Urinary Incontinence
This brief article calculates the proportion of nursing home admissions of the elderly attributable to urinary incontinence (UI) and finds that estimates of the fraction of nursing home admissions attributable to UI exceed those previously assumed and show an imbalance between the sexes. Authors found that the annual cost of nursing home admissions due to UI in 2000 was $6 billion annually. UI policies that support reimbursement for treatments of UI in the community might help prevent or delay institutionalization and offset some of the costs.
E.V.I.dently May 2013
Message From NPCThe Role of Pharmaceuticals in Health Insurance ExchangesOne of the most pressing issues in the implementation of the Affordable Care...
The Role of Pharmaceuticals in Health Insurance Exchanges
As part of the implementation of the Affordable Care Act, a series of state health insurance exchanges are being established across the United States...A Look at Rx Coverage and Cost in the New Health Insurance Exchanges
National Pharmaceutical Chief Science Officer Dr. Robert Dubois will lead a panel discussion, "Capturing the Value of Pharmaceuticals--A Look at Rx...
Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?
A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...
Study Quantifies Impact of Pharmaceuticals on Enhanced Productivity
(WASHINGTON, DC, August 1, 2012)–The costs to employers of chronic health conditions on employee productivity are well documented, but few studies...Pharmaceuticals Play Key Role in Achieving ACO Quality, Cost Goals
WASHINGTON, DC, July 18, 2012–As health care providers set up accountable care organizations (ACOs) and other value-based care programs,...New Survey Shows Employers Eyeing CER, PCORI for Health Information
Washington, DC, June 22, 2011--Employers are aware of comparative effectiveness research (CER) and its potential to answer critical questions about...Study Sheds New Light on the Impact of Medication Adherence, Multiple Chronic Diseases and Health Risks in the Workplace
(Chicago -- June 16, 2011) A new study suggests that while medication adherence is a critical element in reducing the impact of illness, employers...Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?
A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...Living Up to Its Name? The Role of Patient-Centered Research
Anyone who has ever received bad news from his or her health care provider or held a loved one’s hand when a diagnosis was delivered can understand...High Stakes for Setting Research Standards
What is the cost of poorly designed research? In the comparative effectiveness arena, faulty studies could mean that consumers may make important...Framework Helps ACOs Leverage Pharmaceuticals to Realize Quality, Cost Goals
Medications are more than an item on the balance sheet for health care providers. Pharmaceuticals offer a route to manage costs while achieving...
How Do Payers Consider Individual Treatment Effects?
Dr. Robert Epstein, former chief medical officer and senior vice president of medical affairs at Medco Health, explains that heterogeneity, or...Comparative Effectiveness Research in Medicare Decision-Making
At the June 2011 Drug Information Association Annual Meeting, NPC asked Dr. Marcel Salive for his thoughts on how comparative effectiveness research...IBI's Tom Parry on Employers and Health Investments
Integrated Benefits Institute President Tom Parry, PhD, sat down with NPC to discuss how employers today are defining the value of their health...Value-Based Insurance Design
National Pharmaceutical Council President Dan Leonard discusses a new report on Value-Based Insurance Design (VBID) with Dr. A. Mark Fendrick, Co-...The Role of Pharmaceuticals in Health Insurance Exchanges
As part of the implementation of the Affordable Care Act, a series of state health insurance exchanges are being established across the United States...A Look at Rx Coverage and Cost in the New Health Insurance Exchanges
National Pharmaceutical Chief Science Officer Dr. Robert Dubois will lead a panel discussion, "Capturing the Value of Pharmaceuticals--A Look at Rx...CER Communications: Helping Patients Make Informed Decisions
Any guidelines for communicating comparative effectiveness research (CER) must focus on positioning patients to make informed decisions about their...Two Perspectives on Academic Detailing and CER Communication
With hundreds of millions of dollars being invested in comparative effectiveness research (CER), most health care stakeholders acknowledge that there...Research
Formulary Limitations and the Elderly: Results from the Managed Care Outcomes Project
According to this article, the elderly are at partic
Why the Elderly Need Individualized Pharmaceutical Care
A “one drug fits all” approach does not work for eld
Coordinated Pharmaceutical Therapy in Chronic Care: Five Innovative Programs (Executive Summary)
Numerous studies indicate the limitations of a compo
- 1 of 40
- >
Commentary & Testimony
Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?
Living Up to Its Name? The Role of Patient-Centered Research
High Stakes for Setting Research Standards
Framework Helps ACOs Leverage Pharmaceuticals to Realize Quality, Cost Goals
Asymmetry in the Ability to Communicate CER Findings: Ethics and Issues for Informed Decision Making